Therapeutic Effect of Tamoxifen Related to Estrogen Receptor Level

Publisher Website
Google Scholar
Abstract
The antioestrogen tamoxifen (TAM) has been shown to be an effective compound in the endocrine therapy of postmenopausal patients with advanced breast cancer. The overall remission rate observed has been found to be 35%–45% in several studies, depending on whether patients have previously received endocrine therapy (Kiang and Kennedy, 1977; Mouridsen, et al., 1978; Moseson, et al., 1978). This value compares well with that found with other modes of endocrine therapy. A definite advantage of TAM treatment over other forms of endocrine therapy is that side effects are very few and are mild in character (Mouridsen et al., 1978).